

## Special Issue

# Pluripotent Stem Cells: Current Understanding and Future Directions—2nd Edition

### Message from the Guest Editor

Induced pluripotent stem cells (iPSCs) can be generated by reprogramming somatic cells using the delivery of exogenous pluripotent factors such as Oct4, Sox2, Nanog, and Klf4. The delivery methods for pluripotent transgenes include genomic integrated strategies and non-genomic integrated strategies. The overexpression of these pluripotent factors makes somatic cells undergo transformation into pluripotent stem cells through the obtainment of a round morphology, multilineage differentiation abilities, and self-renewal properties. Therefore, iPSCs are similar to embryonic stem cells (ESCs) in that they possess similar regenerative abilities and can differentiate into any cell type in the body, whereas iPSC generation does not face the ethical controversies related to ESC sources. The therapeutic applications of autologous iPSCs hold great promise in tissue engineering and regenerative and personalized medicine. iPSC-differentiated cells may have the potential to be applied to disease cures or the screening of new drugs.

We invite authors in this field to submit original research or review articles related to the important and rapidly progressing field of iPSC-associated medicine.

---

### Guest Editor

Dr. Aline Yen Ling Wang

Center for Vascularized Composite Allotransplantation, Chang Gung Memorial Hospital, Taoyuan 333, Taiwan

---

### Deadline for manuscript submissions

closed (28 February 2026)



## Biomedicines

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.5  
CiteScore 7.8  
Indexed in PubMed



[mdpi.com/si/223536](https://mdpi.com/si/223536)

*Biomedicines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)

[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)





# Biomedicines

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.5  
CiteScore 7.8  
Indexed in PubMed



[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)



## About the Journal

### Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

---

### Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA

2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.2 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2026).